Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in the United States.

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk agreed to pay up to $2 billion for the rights to ... hormones and is in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

and now it looks like we'll have the next generation of these breakthrough weight loss and diabetes medicines on shelves by early next year. Less than five years on from when Novo Nordisk's ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires.In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best ...

An estimated 830 million people have diabetes, with type 2 being the most common. Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...